申请人:Labaz
公开号:US04201725A1
公开(公告)日:1980-05-06
Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH.dbd.CH--R.sub.6 or an alkynyl radical of the formula C.tbd.C--R.sub.6, in which R.sub.6 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.4 and R.sub.5, which are the same or different, each respresent a hydrogen atom, a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 5 carbon atoms or an .omega.-hydroxyalkyl radical containing from 2 to 5 carbon atoms or R.sub.4 and R.sub.5, when they are taken together represent an alkylene radical containing from 2 to 6 carbon atoms, an alkylidene radical containing from 1 to 5 carbon atoms or the radical --CH.sub.2 --CH.sub.2 --O--CH.sub.2 --CH.sub.2 --, R.sub.1, R.sub.2 and R.sub.3 being such that the trisubstituted methylamine radical possesses no more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.
化合物的甲基胺衍生物的公式:##STR1##及其药学上可接受的酸加成盐,其中R.sub.1和R.sub.3分别代表氢原子或含有1至6个碳原子的直链或支链烷基,烯基或炔基基团,R.sub.2代表含有2至7个碳原子的直链或支链烷基,烯基或炔基基团,但当R.sub.2代表公式CH.dbd.CH--R.sub.6的烯基基团或公式C.tbd.C--R.sub.6的炔基基团,其中R.sub.6代表氢原子或含有1至5个碳原子的直链或支链烷基基团时,R.sub.1和R.sub.3分别代表氢原子或烷基基团,R.sub.4和R.sub.5相同或不同,每个都代表氢原子,含有1至5个碳原子的直链或支链烷基,烯基或炔基基团,或者含有2至5个碳原子的ω-羟基烷基基团,或当它们一起取代时,代表含有2至6个碳原子的烷基基团,含有1至5个碳原子的烷基基团或基团--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,其中R.sub.1,R.sub.2和R.sub.3使三取代甲基胺基团不超过13个碳原子。它们可用于治疗帕金森病和纠正由神经精神药物引起的额外锥体外运动障碍。